Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 30

1.

Bruton's tyrosine kinase is at the crossroads of metabolic adaptation in primary malignant human lymphocytes.

Sharif-Askari B, Doyon D, Paliouras M, Aloyz R.

Sci Rep. 2019 Jul 30;9(1):11069. doi: 10.1038/s41598-019-47305-2.

2.

Genome-wide analysis of androgen receptor binding and transcriptomic analysis in mesenchymal subsets during prostate development.

Nash C, Boufaied N, Badescu D, Wang YC, Paliouras M, Trifiro M, Ragoussis I, Thomson AA.

Dis Model Mech. 2019 Jul 25;12(7). pii: dmm039297. doi: 10.1242/dmm.039297.

3.

A Targeted Bivalent Androgen Receptor Binding Compound for Prostate Cancer Therapy.

Chowdhury S, Beitel LK, Lumbroso R, Purisima EO, Paliouras M, Trifiro M.

Horm Cancer. 2019 Feb;10(1):24-35. doi: 10.1007/s12672-018-0353-6. Epub 2018 Dec 18.

PMID:
30565014
4.

Enhanced radiosensitization of enzalutamide via schedule dependent administration to androgen-sensitive prostate cancer cells.

Ghashghaei M, Niazi TM, Heravi M, Bekerat H, Trifiro M, Paliouras M, Muanza T.

Prostate. 2018 Jan;78(1):64-75. doi: 10.1002/pros.23445. Epub 2017 Nov 14. Erratum in: Prostate. 2018 Feb;78(3):239.

PMID:
29134684
5.

Real time plasmonic qPCR: how fast is ultra-fast? 30 cycles in 54 seconds.

Roche PJR, Najih M, Lee SS, Beitel LK, Carnevale ML, Paliouras M, Kirk AG, Trifiro MA.

Analyst. 2017 May 21;142(10):1746-1755. doi: 10.1039/c7an00304h. Epub 2017 Apr 26.

PMID:
28443837
6.

Prostate-specific membrane antigen-directed nanoparticle targeting for extreme nearfield ablation of prostate cancer cells.

Lee SS, Roche PJ, Giannopoulos PN, Mitmaker EJ, Tamilia M, Paliouras M, Trifiro MA.

Tumour Biol. 2017 Mar;39(3):1010428317695943. doi: 10.1177/1010428317695943.

PMID:
28351335
7.

Correction: Engineering Multi-Walled Carbon Nanotube Therapeutic Bionanofluids to Selectively Target Papillary Thyroid Cancer Cells.

Dotan I, Roche PJ, Tamilia M, Paliouras M, Mitmaker EJ, Trifiro MA.

PLoS One. 2016 Jun 16;11(6):e0158022. doi: 10.1371/journal.pone.0158022. eCollection 2016.

8.

Engineering Multi-Walled Carbon Nanotube Therapeutic Bionanofluids to Selectively Target Papillary Thyroid Cancer Cells.

Dotan I, Roche PJ, Paliouras M, Mitmaker EJ, Trifiro MA.

PLoS One. 2016 Feb 22;11(2):e0149723. doi: 10.1371/journal.pone.0149723. eCollection 2016. Erratum in: PLoS One. 2016;11(6):e0158022.

9.

Characterization of the NPC1L1 gene and proteome from an exceptional responder to ezetimibe.

Schweitzer M, Makhoul S, Paliouras M, Beitel LK, Gottlieb B, Trifiro M, Chowdhury SF, Zaman NM, Wang E, Davis H, Chalifour LE.

Atherosclerosis. 2016 Mar;246:78-86. doi: 10.1016/j.atherosclerosis.2015.12.032. Epub 2015 Dec 24.

PMID:
26761771
10.

Proteomic-coupled-network analysis of T877A-androgen receptor interactomes can predict clinical prostate cancer outcomes between White (non-Hispanic) and African-American groups.

Zaman N, Giannopoulos PN, Chowdhury S, Bonneil E, Thibault P, Wang E, Trifiro M, Paliouras M.

PLoS One. 2014 Nov 19;9(11):e113190. doi: 10.1371/journal.pone.0113190. eCollection 2014.

11.

Coexistence of malignant struma ovarii and cervical papillary thyroid carcinoma.

Leong A, Roche PJ, Paliouras M, Rochon L, Trifiro M, Tamilia M.

J Clin Endocrinol Metab. 2013 Dec;98(12):4599-605. doi: 10.1210/jc.2013-1782. Epub 2013 Nov 11.

PMID:
24217901
12.

Signaling network assessment of mutations and copy number variations predict breast cancer subtype-specific drug targets.

Zaman N, Li L, Jaramillo ML, Sun Z, Tibiche C, Banville M, Collins C, Trifiro M, Paliouras M, Nantel A, O'Connor-McCourt M, Wang E.

Cell Rep. 2013 Oct 17;5(1):216-23. doi: 10.1016/j.celrep.2013.08.028. Epub 2013 Sep 26.

13.

Cancer systems biology in the genome sequencing era: part 2, evolutionary dynamics of tumor clonal networks and drug resistance.

Wang E, Zou J, Zaman N, Beitel LK, Trifiro M, Paliouras M.

Semin Cancer Biol. 2013 Aug;23(4):286-92. doi: 10.1016/j.semcancer.2013.06.001. Epub 2013 Jun 18. Review.

PMID:
23792107
14.

Cancer systems biology in the genome sequencing era: part 1, dissecting and modeling of tumor clones and their networks.

Wang E, Zou J, Zaman N, Beitel LK, Trifiro M, Paliouras M.

Semin Cancer Biol. 2013 Aug;23(4):279-85. doi: 10.1016/j.semcancer.2013.06.002. Epub 2013 Jun 19. Review.

PMID:
23791722
15.

Mechanisms mediating spinal and bulbar muscular atrophy: investigations into polyglutamine-expanded androgen receptor function and dysfunction.

Beitel LK, Alvarado C, Mokhtar S, Paliouras M, Trifiro M.

Front Neurol. 2013 May 15;4:53. doi: 10.3389/fneur.2013.00053. eCollection 2013.

16.

The androgen receptor gene mutations database: 2012 update.

Gottlieb B, Beitel LK, Nadarajah A, Paliouras M, Trifiro M.

Hum Mutat. 2012 May;33(5):887-94. doi: 10.1002/humu.22046. Epub 2012 Mar 13.

PMID:
22334387
17.

Dynamic rewiring of the androgen receptor protein interaction network correlates with prostate cancer clinical outcomes.

Paliouras M, Zaman N, Lumbroso R, Kapogeorgakis L, Beitel LK, Wang E, Trifiro M.

Integr Biol (Camb). 2011 Oct;3(10):1020-32. doi: 10.1039/c1ib00038a. Epub 2011 Sep 7.

PMID:
21901193
18.

Impact of cytogenetic and genomic aberrations of the kallikrein locus in ovarian cancer.

Bayani J, Paliouras M, Planque C, Shan SJ, Graham C, Squire JA, Diamandis EP.

Mol Oncol. 2008 Oct;2(3):250-60. doi: 10.1016/j.molonc.2008.07.001. Epub 2008 Jul 22.

19.
20.

High-throughput screening identifies cardiac glycosides as potent inhibitors of human tissue kallikrein expression: implications for cancer therapies.

Prassas I, Paliouras M, Datti A, Diamandis EP.

Clin Cancer Res. 2008 Sep 15;14(18):5778-84. doi: 10.1158/1078-0432.CCR-08-0706.

21.

An AKT activity threshold regulates androgen-dependent and androgen-independent PSA expression in prostate cancer cell lines.

Paliouras M, Diamandis EP.

Biol Chem. 2008 Jun;389(6):773-80. doi: 10.1515/BC.2008.072.

PMID:
18627304
22.

Intracellular signaling pathways regulate hormone-dependent kallikrein gene expression.

Paliouras M, Diamandis EP.

Tumour Biol. 2008;29(2):63-75. doi: 10.1159/000135686. Epub 2008 Jun 2.

PMID:
18515984
23.

Bicaudal-C recruits CCR4-NOT deadenylase to target mRNAs and regulates oogenesis, cytoskeletal organization, and its own expression.

Chicoine J, Benoit P, Gamberi C, Paliouras M, Simonelig M, Lasko P.

Dev Cell. 2007 Nov;13(5):691-704.

24.

Human tissue kallikreins: the cancer biomarker family.

Paliouras M, Borgono C, Diamandis EP.

Cancer Lett. 2007 Apr 28;249(1):61-79. Epub 2007 Jan 31. Review.

PMID:
17275179
25.

Coordinated steroid hormone-dependent and independent expression of multiple kallikreins in breast cancer cell lines.

Paliouras M, Diamandis EP.

Breast Cancer Res Treat. 2007 Mar;102(1):7-18. Epub 2006 Aug 8.

PMID:
16897430
26.

The kallikrein world: an update on the human tissue kallikreins.

Paliouras M, Diamandis EP.

Biol Chem. 2006 Jun;387(6):643-52. Review.

PMID:
16800725
27.

Effect of testosterone administration on serum and urine kallikrein concentrations in female-to-male transsexuals.

Slagter MH, Scorilas A, Gooren LJ, de Ronde W, Soosaipillai A, Giltay EJ, Paliouras M, Diamandis EP.

Clin Chem. 2006 Aug;52(8):1546-51. Epub 2006 Jun 15.

28.

Serum and urine tissue kallikrein concentrations in male-to-female transsexuals treated with antiandrogens and estrogens.

Slagter MH, Gooren LJ, de Ronde W, Soosaipillai A, Scorilas A, Giltay EJ, Paliouras M, Diamandis EP.

Clin Chem. 2006 Jul;52(7):1356-65. Epub 2006 Apr 27.

29.

Nonmuscle myosin promotes cytoplasmic localization of PBX.

Huang H, Paliouras M, Rambaldi I, Lasko P, Featherstone M.

Mol Cell Biol. 2003 May;23(10):3636-45.

30.

Visualization of double-stranded RNAs from the myotonic dystrophy protein kinase gene and interactions with CUG-binding protein.

Michalowski S, Miller JW, Urbinati CR, Paliouras M, Swanson MS, Griffith J.

Nucleic Acids Res. 1999 Sep 1;27(17):3534-42.

Supplemental Content

Loading ...
Support Center